# National Resilience, LLC.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/national-resilience

- Industry: Biotechnology
- Headquarters: Blue Ash, US
- Website: www.resilience.com
- Total disclosed funding: $755M
- Latest round: Series B (Oct 23, 2020)
- Investors on record: 6

## About

Founded in 2020 by Drew Oetting and Rahul Singhvi, and based in Blue Ash, OH, National Resilience, Inc. specializes in biomanufacturing solutions for complex medicines, particularly in cell and gene therapies, biologics, and viral vector production. It operates as a Contract Development and Manufacturing Organization (CDMO) focusing on biomanufacturing solutions for complex medicines, particularly in the realms of cell and gene therapies, biologics, and viral vector production. National Resilience, Inc. has raised a total of USD 2.46 billion across 6 rounds of funding, the most recent being a venture debt round in which the company secured USD 410 million from the U.S. Department of Defense. This firm is valued at USD 9.11 billion. Its principal offerings, such as Sprout Solutions™, DAR-T™, and Auto-T™, cater to the entire lifecycle of drug development—from initial concept to clinical readiness—by providing tailored manufacturing solutions that enhance transparency, speed, and scalability. The company’s robust capabilities encompass PAD and GMP manufacturing for monoclonal antibodies and recombinant proteins, as well as specialized facilities for AAV and LVV viral vector production. Clients range from small biotech firms to larger pharmaceutical companies in global markets, including the U.S., Europe, Asia, and the Middle East, who seek to leverage Resilience's advanced technologies and expertise to accelerate their therapeutic innovations. Resilience generates revenue through a variety of transaction structures primarily focused on B2B relationships with pharmaceutical and biotechnology companies. Clients engage with Resilience for services that include drug substance manufacturing and fill/finish operations, often structured as project-based contracts or long-term partnerships. Key offerings such as the Essential AAV & LVV program and Build Your Resilience™ provide clients with access to critical drug manufacturing support under customized terms. The revenue model is characterized by agreements that prioritize flexibility to meet specific project needs, often involving comprehensive quality assurance and supply chain management. These partnerships are designed to ensure that clients receive the necessary resources and support while enhancing the overall efficiency of their drug development processes.

## Funding rounds

- Series B, Oct 23, 2020, $755M — ARCH Venture Partners, New Enterprise Associates, Lux Capital, GV, 8VC, Magnetic

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series B
- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series B
- Lux Capital (https://capitalatlas.ai/funds/lux-capital) — Series B
- GV (https://capitalatlas.ai/funds/gv) — Series B
- 8VC (https://capitalatlas.ai/funds/8vc) — Series B
- Magnetic (https://capitalatlas.ai/funds/magnetic) — Series B